

EXHIBIT 6

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

AMGEN INC.,)	
)	
Plaintiff,)	
)	
v.)	Civil Action No.: 05-12237 WGY
)	
)	
F. HOFFMANN-LAROCHE)	
LTD., a Swiss Company, ROCHE)	
DIAGNOSTICS GmbH, a German)	
Company and HOFFMANN LAROCHE)	
INC., a New Jersey Corporation,)	
)	
Defendants.)	
_____)	

**DECLARATION OF WENDY A. WHITEFORD IN SUPPORT OF
PLAINTIFF AMGEN INC.'S MEMORANDUM IN SUPPORT OF ITS MOTION FOR
RECONSIDERATION OR CLARIFICATION OF THE NOVEMBER 6, 2006 ORDER**

1. I previously submitted a declaration to this Court on October 23, 2006 (Docket No. 130). The statements in that declaration were true at the time I made them and remain true today, except that my title has changed.

2. As I stated in my October 23, 2006 declaration, I have been involved in litigation concerning the patents-in-suit and related U.S. and foreign patents since I joined Amgen in 1996. Historically, I have had both supervisory responsibilities, as well as responsibility for performing litigation tasks necessary to prepare and conduct proceedings before a court, such as for example, drafting and editing briefs, pleadings, expert statements, witness declarations, direct and cross-examination questions, and proposed findings of fact and conclusions of law, as well as selecting evidence and preparing witnesses for deposition and trial. One or another of these patents or related applications has been involved in various patent infringement litigations and validity challenges continuously during my 10 year tenure with Amgen. The type of involvement which I have had on these cases and which Amgen expects of me and the other in-house patent litigation attorneys participating in this case, has afforded me specialized knowledge as to the legal and scientific issues implicated by these patents and erythropoiesis stimulating proteins which is not duplicated by outside counsel.

3. In Roche's Opposition Motion of November 3, 2006, Roche submitted a document that included my name as a member on a Competitive Anemia Task Force – Core Team (“CAT-Core Team”). This CAT-Core Team was formed in January 2005 and had no more than three meetings in the first half of 2005. To the best of my recollection, I participated in two of these meeting. By June of 2005 the team had disbanded. Ms. Howard was not a member of the CAT-Core Team, as alleged by Roche.

4. I was a member of the CAT-Core Team to carry out my responsibility as one of the lawyers preparing the case now pending before this court. Consistent with my October 23 Declaration, my role on this team was limited to providing legal updates, providing legal advice as Amgen contemplated the now pending litigation, and providing referrals to other lawyers in

